XML 42 R35.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Schedule of Calculation for Basic and Diluted Net Loss Per Share

The following table presents the calculation for basic and diluted net loss per share (in thousands, except share and per share data):


		Three Months Ended March 31,
		2025				2024
Numerator:
Net loss		$	(68,037	)		$	(64,743	)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares			—				(27,807	)
Cumulative undeclared dividends on Series C preferred shares			—				(506	)
Net loss attributable to common stockholders		$	(68,037	)		$	(93,056	)
Denominator:
Weighted-average common shares outstanding, basic and diluted			170,506				63,430
Net loss per share attributable to common stockholders, basic and diluted		$	(0.40	)		$	(1.47	)

Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share

The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 10, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of the warrant, potentially dilutive shares are based on the latest equity financing price. The warrant was terminated for no consideration on December 31, 2024.


		As of March 31,
		2025				2024
Stock options outstanding			—				210,000
Convertible preferred stock			—				63,603,084
Astrazeneca warrant			—				1,744,991
Deep 6 holdback liability			17,372				—
SEngine holdback liability			—				41,007
Unvested RSUs			5,761,861				—
Unvested RSAs			26,059				—
Allen & Company warrant			—				150,000
Total potentially dilutive shares			5,805,292				65,749,082